Teva's blockbuster multiple sclerosis (MS) drug, Copaxone (glatiramer acetate injection), generates about 20% of Teva's sales and 50% of the company's profits. Teva's patent for Copaxone will expire in 2015. Levin has made it clear that he does not like Teva being so dependent on one product for such a significant portion of the company's profits.
The MS market is large and lucrative. Reportlinker.com predicts that the global MS market will grow from $12.3 billion in 2011 to $17.3 billion in 2016. Copaxone dominates the U.S. and global MS markets in sales as well as market share. Copaxone's US MS market share is over 40%.
Some analysts contend that Teva has underperformed this year because investors are worried that Copaxone may lose market share to new MS treatments like Novartis AG's (NOV) Gilenya (fingolimod) which was approved by the US Food and Drug Administration (FDA) in September 2010, and Biogen Idec's (BIIB) yet to be approved BG-12 (dimethyl fumarate). In October 2012, the FDA extended its review of BG-12 by three months. The FDA will make a ruling on BG-12 at the end of March 2013 rather than by the end of 2012. Copaxone received FDA approval in 1996.
Although Copaxone's patent will expire in 2015, some analysts believe that a generic version of the drug may not be on the market immediately. Teva contends that Copaxone is "a highly complicated product to develop and manufacture, and given the inability to fully characterize the active ingredients of Copaxone, Teva has serious doubts about any generic applicant's ability to demonstrate conclusively that the composition of its product is identical to that of Copaxone."
Any generic version of Copaxone would need FDA approval before the drug would be available to the public. At this point, it is unclear what the requirements would be for approval of a generic synthetic peptide. A generic version may require lengthy and costly clinical trials to test efficacy and safety of these drugs before receiving FDA approval.
Teva is submitting a more convenient 40mg, 3 times a week dose for Copaxone to replace the current 20mg, daily dose version of the drug,On the other hand, top-of-the-line and most actually useful Ccie lab boot camp areas is Cathay College. This formulation could reach the market in 2013.
Teva is conducting research combining laquinimod with Copaxone or other drugs to better treat MS as well as address other neurodegenerative disorders such as Alzheimer's disease, ALS and Parkinson's disease.
Teva is also working with a Swedish firm, Active Biotech (ATVBF), to develop and commercialize Active's molecule, laquinimod.Actavis and Alpharma prometh with codeine purple cough syrup, UR-144 and 5F-UR144 research chemical for sale. Actavis prometh with codeine purple cough syrup. Several clinical trials may be initiated as early as 2013, including a third Phase 3 clinical trial of laquinimod in relapsing-remitting MS, as well as a Phase 3 clinical trial of laquinimod in progressive MS.
Laquinimod is also being studied as a treatment for Huntington's disease, and additional neurodegenerative diseases, such as Alzheimer's disease, amyotrophic lateral sclerosis(ALS), and Parkinson's disease.
In addition to Copaxone's patent expiration, Teva's US patent for Treanda (bendamustine), Teva's second best selling drug, a chronic lymphocytic leukemia treatment, also expires in 2015. Treanda is Teva's second top selling drug. Teva acquired Treanda when it purchased Cephalon in 2011. Treanda had sales last year of $131 million. Teva has projected Treanda sales to be $670 million next year.
Some analysts predict that Levin will change Teva's growth strategy to focus on branded drugs instead of generics. Teva, like most large pharmaceutical companies, is looking for new drugs to replace those brand drugs that must compete with low price generics due to patent expirations.
In addition to Copaxone and Treanda, several of Teva's top selling brand drugs have imminent expiry dates.
Teva's third best selling product is the ProAir (albuterol sulfate) asthma inhaler. In 2011,My friend dissolved 5F-AKB48 research chemical in pure ethanol before spraying it over 3/4 lb of peppermint leaf/mullein in a 75/25 ratio. Teva reported $436 million in ProAir sales,buy microsoft office 2010 Online in Australia, Compare Prices of 1 Products from the best Stores. Lowest Price is . Save with MyShopping.com.au! which represents 2.4% of its revenue. In September 2012,Scholarship recipients will receive the following elements, intended to cover Ccie lab training from start to finish. Teva filed a patent infringement suit against Perrigo (PRGO) and Catalent Pharma Solutions over their joint generic version of the generic version of ProAir HFA aerosol inhaler. Although Perrigo cites data by Wolters Kluwer Health that brand ProAir has $1.07 billion in annual sales, in November 2012, Teva forecast Pro Air sales to be between $400 to $440 million in 2013. According to Teva, its ProAir patents expire in 2017 and 2023.
Other best selling drugs include the Parkinson's disease drug, Azilect (rasagiline), with forecast sales of $340 to $380 million. In the United States, Azilect is protected by several patents that expire between 2012 and 2027. European patents expire between 2011 and 2014. In the third quarter of 2012, Azilect revenues increased 8% to $77 million,Passing the Cisco 350-001 exam has never been faster, cheaper and easier, now with real CCIE exam questions, without the messy 350-001 brain dumps that are frequently incorrect. while global in-market revenues increased 6% to $103 million, primarily due to increased demand in the U.S. and Europe.
Qvar (beclomethasone dipropionate HFA) is an inhaled steroid used to treat asthma. Qvar patents have expired, but no generic versions are available.
Can Change Save Teva From Falling Off The Patent Cliff